Study Summary
This trial is testing a new drug, Acalabrutinib, as a treatment for Waldenstrom's Macroglobulinemia, a cancer of the blood. The study will last for one year, and participants will take the drug twice a day.
Treatment Effectiveness
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Up to 6 year post first dose
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Single arm intervention
1 of 1
Experimental Treatment
59 Total Participants · 1 Treatment Group
Primary Treatment: Acalabrutinib · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 13 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has Acalabrutinib gone through the FDA's approval process?
"Acalabrutinib's safety is estimated to be a 2. This is due to it being in Phase 2 of clinical trials, where there is data supporting its safety but not yet efficacy." - Anonymous Online Contributor
What does the research say about Acalabrutinib's efficacy?
"Acalabrutinib was first evaluated in 1993 at the National Institutes of Health Clinical Center. As of now, 899 clinical trials have been completed with 511 more currently underway; a large portion these are based in Ottawa, Canada." - Anonymous Online Contributor
What are the benefits of Acalabrutinib?
"Acalabrutinib has been shown to be effective in treating patients with diffuse large b-cell lymphoma (DLBCL), Hodgkin disease, and various other B-cell lymphomas." - Anonymous Online Contributor
In how many different places is this trial taking place?
"The Ottawa Hospital, QEII Health Sciences Centre, Sunnybrook Health Sciences Centre, and 4 other locations are running this trial." - Anonymous Online Contributor
How many individuals are experiencing this treatment as part of the research?
"In order to complete this clinical study, 59 patients that fit the pre-determined inclusion criteria must be recruited. These potential participants can be sourced from medical facilities such as The Ottawa Hospital located in Ottawa, Ontario and QEII Health Sciences Centre situated in Halifax, Nova Scotia." - Anonymous Online Contributor
Is patient recruitment for this trial still open?
"Yes, this trial is still recruiting patients. Information on clinicaltrials.gov reveals that the listing was first posted on March 2nd 2021 and updated most recently on July 23rd 2021." - Anonymous Online Contributor